Prometheus Announces Breakthrough e-Kerosene Pathway to Make Cost-Competitive SAF and Diesel from Electricity and Air
14.1.2026 14:57:00 CET | Business Wire | Press Release
Prometheus Fuels today announced its revolutionary new pathway for producing synthetic paraffinic kerosene (the basis for SAF jet fuel and e-diesel) from direct air capture of CO2 and off-grid renewable electricity. The new Prometheus e-kerosene pathway makes Fischer-Tropsch synthesis obsolete, reducing the cost to make e-fuels by more than 80 percent compared to the century-old technology. It is also the first process in history to make kerosene from electricity and atmospheric CO2 without using hydrogen. The kerosene produced is 100 percent carbon neutral. Two independent engineering reviews confirmed demonstration of the new pathway using commercial-scale cells.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114310118/en/
Because the Prometheus e-kerosene pathway operates at ambient temperatures and pressures, it uses much less expensive equipment than the high-temperature, high-pressure Fischer-Tropsch process. This is just one example of several major cost drivers of conventional e-fuel production Prometheus has eliminated with its breakthrough e-kerosene pathway. ©Prometheus Fuels
The announcement follows the company’s recent milestone achievement of completing a one-year pilot-scale demonstration of its DAC-to-fuels technology platform, producing e-methanol at its Titan Forge Alpha pilot facility. The pilot and its operating data were validated by two independent engineering reviews, in November and December of 2025.
For the first time, Prometheus is releasing details of its new 100 percent electrochemical synthetic paraffinic kerosene pathway, which uses CO2 captured from the air using the company’s proprietary “No-Desorb DAC” process. A key breakthrough that made the new kerosene pathway possible is a process the company calls “electrochemical oligomerization.” Oligomerization is the combining of smaller monomers into larger molecules, like hydrocarbons. One example of this is carbon-carbon chain lengthening. In the Fischer-Tropsch process, this chain lengthening occurs due to the high pressures and temperatures that process requires. It is these extreme operating conditions, which require expensive equipment and 24-7, grid-connected power, that keep the cost of Fischer-Tropsch e-fuels permanently high. In contrast, Prometheus has developed the ability to achieve its carbon-carbon chain lengthening using electromagnetic fields and electric currents in water at room temperature and atmospheric pressure. With these ambient operating conditions, the Prometheus process uses equipment that is much less expensive and can be powered by intermittent, off-grid solar, allowing access to the lowest energy input costs.
The new pathway eliminates the major cost drivers of conventional e-fuels systems. It does not desorb CO2 into a pure gas stream; does not use hydrogen; does not rely on high-temperature or high-pressure reactors; and was purpose-built to operate on intermittent off-grid renewable electricity – the cheapest electrons in the world – avoiding the high cost and geographic constraints of being connected to a grid. There is also no need for distillation. Kerosene forms directly in Prometheus’ Faraday Reactor hydrocarbon electrolyzer and self-separates from water, at room temperature and atmospheric pressure, producing finished kerosene fuel. Notably, the Prometheus e-kerosene pathway has linear cost scaling, allowing it to achieve its low costs across a wide range of production scales, from pilot systems to commercial plants.
“Our new kerosene pathway takes e-fuels beyond decarbonization to direct economic competition with oil-based fuels,” said Rob McGinnis, founder and CEO of Prometheus. “Our pathway puts three holy grails of energy within reach: a new source of energy for data centers, limitless low-cost SAF, and unblockadeable fuel logistics for defense. The implications of this new technology – the advantages it creates for energy independence and national security – are profound.”
Until now, Prometheus had shared only high-level descriptions of its technology while it focused on building and securing its patent and trade secret portfolio. With its IP portfolio secure, Prometheus is able to release more details about its technology and competitive advantages in global commodity energy markets.
About Prometheus Fuels
Prometheus is the global leader in fuels made from air and electricity to power AI data centers, factories, ships, vehicles, and aircraft. The company’s patented technology produces carbon neutral fuels that are cost-competitive with commodity fossil fuel prices without subsidies. Designed to run off-grid, Prometheus offers an infinitely scalable source of new energy, transforming intermittent renewable electricity into firm dispatchable 24/7 power, anywhere it is needed. Backed by top-tier investors including Maersk, BMW, and Y Combinator, Prometheus is redefining the future of energy. Learn more at prometheusfuels.com and prometheusfuels.AI.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260114310118/en/
Contacts
Media Contact
Amanda Martinez for Prometheus Fuels: press@prometheusfuels.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom